Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRAS^G12C(ON) inhibitor, in patients with or without prior KRAS^G12C(OFF) inhibitor treatment

Mol Cancer Ther (2023) 22 (12_Supplement): PR014.

https://doi.org/10.1158/1535-7163.TARG-23-PR014

Published: 01 December 2023

View article titled, Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment

Journal Articles

Abstract A036: A subset of lung adenocarcinomas defined by high-level ERBB2 amplification is vulnerable to HER2-targeted therapy

Igor Odintsov, Maisam Makarem, Sara E. Bachert, Tom Zhang, Romel Somwar, Pasi A. Jänne, Lynette M. Sholl

Mol Cancer Ther (2023) 22 (12_Supplement): A036.

https://doi.org/10.1158/1535-7163.TARG-23-A036

Published: 01 December 2023

View article titled, Abstract A036: A subset of lung adenocarcinomas defined by high-level ERBB2 amplification is vulnerable to HER2-targeted therapy

Journal Articles

Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

Magda Bahcall, Cloud P. Paweletz, Yanan Kuang, Luke J. Taus, Taebo Sim, Nam Doo Kim, Kshiti H. Dholakia, Christie J. Lau, Prafulla C. Gokhale, Pratik R. Chopade, Fangxin Hong, Zihan Wei, Jens Köhler, Paul T. Kirschmeier, Jiannan Guo, Sujuan Guo, Stephen Wang, Pasi A. Jänne

Mol Cancer Ther (2022) 21 (2): 322–335.

https://doi.org/10.1158/1535-7163.MCT-21-0344

Published: 08 February 2022

View article titled, Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

Includes: Supplementary data

Journal Articles

ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer

Mol Cancer Ther (2021) 20 (4): 641–654.

https://doi.org/10.1158/1535-7163.MCT-20-0531

Published: 01 April 2021

View article titled, ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer

Journal Articles

Abstract A105: Credentialing the concept of “co-clinical trials”: Utility of lung cancer PDX models derived from patients on AZD9291 clinical trials

Sangeetha S. Palakurthi, Man Xu, Amanda Redig, Michael Dills, Prafulla Gokhale, Jihyun Choi, Atsuko Ogino, Yanan Kuang, Nora Feeney, Cloud Paweletz, Paul Kirschmeier, Jessie English, Darren Cross, Pasi A. Janne

Mol Cancer Ther (2015) 14 (12_Supplement_2): A105.

https://doi.org/10.1158/1535-7163.TARG-15-A105

Published: 01 December 2015

View article titled, Abstract A105: Credentialing the concept of “co-clinical trials”: Utility of lung cancer PDX models derived from patients on AZD9291 clinical trials

Journal Articles

Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint

Mol Cancer Ther (2015) 14 (12_Supplement_2): B96.

https://doi.org/10.1158/1535-7163.TARG-15-B96

Published: 01 December 2015

View article titled, Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint

Journal Articles

Abstract B105: Characterization of the activity of AZD9291 in patients (pts) with T790M ‘negative’ advanced non-small cell lung cancer (aNSCLC)

Pasi A. Jänne, Enriqueta Felip, Dong-Wan Kim, Thomas John, Daniel E. Haggstrom, Myung-Ju Ahn, Kenneth S. Thress, Suzanne C. Jenkins, Helen Mann, Mireille V. Cantarini, Simon P. Dearden, James Chih-Hsin Yang

Mol Cancer Ther (2015) 14 (12_Supplement_2): B105.

https://doi.org/10.1158/1535-7163.TARG-15-B105

Published: 01 December 2015

View article titled, Abstract B105: Characterization of the activity of AZD9291 in patients (pts) with T790M ‘negative’ advanced non-small cell lung cancer (aNSCLC)

Journal Articles

Abstract B104: Differentiating somatic and germline variants using targeted next-generation sequencing (NGS) of cell-free plasma DNA (cfDNA)

Geoffrey R. Oxnard, Adrian G. Sacher, Ryan S. Alden, Nora B. Feeney, Jennifer C. Heng, Rebecca J. Nagy, Richard B. Lanman, Cloud P. Paweletz, Pasi A. Janne

Mol Cancer Ther (2015) 14 (12_Supplement_2): B104.

https://doi.org/10.1158/1535-7163.TARG-15-B104

Published: 01 December 2015

View article titled, Abstract B104: Differentiating somatic and germline variants using targeted next-generation sequencing (NGS) of cell-free plasma DNA (cfDNA)

Journal Articles

Abstract PL04-02: Targeting MEK in KRAS mutant lung cancer.

Pasi A. Jänne

Mol Cancer Ther (2013) 12 (11_Supplement): PL04-02.

https://doi.org/10.1158/1535-7163.TARG-13-PL04-02

Published: 01 November 2013

View article titled, Abstract PL04-02: Targeting MEK in KRAS mutant lung cancer.

Journal Articles

TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation

Wataru Okamoto, Isamu Okamoto, Kaoru Tanaka, Erina Hatashita, Yuki Yamada, Kiyoko Kuwata, Haruka Yamaguchi, Tokuzo Arao, Kazuto Nishio, Masahiro Fukuoka, Pasi A. Jänne, Kazuhiko Nakagawa

Mol Cancer Ther (2010) 9 (10): 2785–2792.

https://doi.org/10.1158/1535-7163.MCT-10-0481

Published: 10 October 2010

View article titled, TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation

Journal Articles

Abstract A254: A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors

Pasi A. Janne, Enriqueta Felip, Susana Cedrés, Steven J. Cohen, Jeffrey A. Engelman, Joan Lucca, Pablo Martínez, Margaret von Mehren, Steven B. Gendreau, Katherine K. Lara, Jean‐Francois Martini, Roger B. Cohen

Mol Cancer Ther (2009) 8 (12_Supplement): A254.

https://doi.org/10.1158/1535-7163.TARG-09-A254

Published: 10 December 2009

View article titled, Abstract A254: A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors

NARROW

Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRAS^G12C(ON) inhibitor, in patients with or without prior KRAS^G12C(OFF) inhibitor treatment

Abstract A036: A subset of lung adenocarcinomas defined by high-level ERBB2 amplification is vulnerable to HER2-targeted therapy

Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance

ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer

Abstract A105: Credentialing the concept of “co-clinical trials”: Utility of lung cancer PDX models derived from patients on AZD9291 clinical trials

Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint

Abstract B105: Characterization of the activity of AZD9291 in patients (pts) with T790M ‘negative’ advanced non-small cell lung cancer (aNSCLC)

Abstract B104: Differentiating somatic and germline variants using targeted next-generation sequencing (NGS) of cell-free plasma DNA (cfDNA)

Abstract PL04-02: Targeting MEK in KRAS mutant lung cancer.

TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation

Abstract A254: A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only